We report the use of coronary stenting to treat disease in an anomalous coronary artery. The patient had a single coronary artery with anomalous left anterior descending artery arising from the right sinus of Valsalva and coursing between the aorta and pulmonary artery. Although balloon angioplasty
Fatal stent thrombosis following successful treatment of coronary artery rupture in an octogenarian
β Scribed by Hennessy, Terence G. ;McCann, Hugh A. ;Sugrue, Declan D.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 75 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0098-6569
No coin nor oath required. For personal study only.
β¦ Synopsis
Primary intracoronary stenting of a calcified left anterior descending coronary artery stenosis was complicated by within-stent coronary artery rupture and subsequent cardiac tamponade. Despite pericardiocentesis and sealing of the perforation by additional stent placement, subsequent stent thrombosis resulted in anterior myocardial infarction and fatal cardiogenic shock.
π SIMILAR VOLUMES
We describe a case of type 2 coronary artery perforation in a 73-year-old man undergoing coronary artery rotablation and stenting with abciximab therapy. The coronary artery perforation was successfully treated by coil embolization with Trufill pushable coils made from platinum alloy and synthetic f
A 69yrsld man had chronic transient Ischemia attacks due to severe stenosis of the lntracranial portion of the right carotid artery. After failure of both antlpiateiet and anticoagulant therapy, treatment was successful wlth percutaneous translumlnal angioplasty and a coronary Paimaz-Schatz stent. U
Heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) is a severe complication of heparin caused by an antibody response to the heparin-platelet factor 4 complex which results in severe thrombosis. Heparin rechallenge in HllTS patients carries a high risk of inducing thrombosis. Antithrom
## Abstract This report describes the 4βyear clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimusβeluting stent (EES), or the TAXUS paclitaxelβeluting stent. At 4βyear clinical followβup, which was available in 256 (85.3%) patients, treat